Gemma Bruera
Overview
Explore the profile of Gemma Bruera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ricevuto E, Morgani C, Seri F, Bruera G
Asian J Androl
. 2024 Sep;
26(6):567-568.
PMID: 39327840
No abstract available.
2.
Guadagni S, Masedu F, Fiorentini G, Sarti D, Fiorentini C, Guadagni V, et al.
BMC Cancer
. 2022 Jun;
22(1):660.
PMID: 35710393
Background: Patients with unresectable recurrent rectal cancer (RRC) or colorectal cancer (CRC) with liver metastases, refractory to at least two lines of traditional systemic therapy, may receive third line intraarterial...
3.
Bruera G, Pepe F, Malapelle U, Di Staso M, Dal Mas A, Di Giacomo D, et al.
Ann Transl Med
. 2021 Jul;
9(12):1027.
PMID: 34277827
In fit metastatic colorectal cancer (MCRC), multidisciplinary treatment strategy integrating intensive FIr-B/FOx triplet chemotherapy associated to bevacizumab and secondary metastasectomies significantly improved clinical outcomes up to progression-free survival (PFS) 17...
4.
Bruera G, Ricevuto E
Pharmgenomics Pers Med
. 2020 Nov;
13:601-617.
PMID: 33235483
Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings, increased overall survival (OS) with individual variability of toxicity. Pharmacogenomic...
5.
Guadagni S, Farina A, Cappabianca L, Sebastiano M, Maccarone R, Zelli V, et al.
Int J Mol Sci
. 2020 Nov;
21(21).
PMID: 33153070
Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis...
6.
Bruera G, DAndrilli A, Simmaco M, Guadagni S, Rendina E, Ricevuto E
Front Oncol
. 2020 Aug;
10:1155.
PMID: 32850329
Intensive oncological treatment integrated with resection of metastases raised the clinical outcome of metastatic colorectal cancer (MCRC). In clinical practice, complex evaluation of clinical (age, performance status, comorbidities), and biological...
7.
Bruera G, Ricevuto E
Front Oncol
. 2020 Mar;
10:172.
PMID: 32154172
Cancer treatments induce symptoms/signs superimposing on individual patient's clinical status, determining heterogenous toxicity syndromes (TS). We reviewed intensive first line triplet chemotherapy-based regimens in metastatic gastro-intestinal cancers (mGI), based on...
8.
Guadagni S, Clementi M, Mackay A, Ricevuto E, Fiorentini G, Sarti D, et al.
J Cancer Res Clin Oncol
. 2020 Feb;
146(5):1273-1290.
PMID: 32088781
Background: Hepatic artery infusion (HAI) and drug selection by liquid biopsy precision oncotherapy are under investigation for the multidisciplinary treatment of unresectable colorectal liver metastases (CRCLM) in progression after systemic...
9.
Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay A, et al.
J Cancer Res Clin Oncol
. 2019 Oct;
146(1):205-219.
PMID: 31620896
Background: Third line innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have both been proposed for the treatment of unresectable not responsive recurrent rectal cancer (URRC). In...
10.
Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, et al.
BMC Cancer
. 2019 Oct;
19(1):960.
PMID: 31619203
Background: Neuroendocrine tumors (NETs) are heterogeneous, widely distributed tumors arising from neuroendocrine cells. Gastrointestinal (GI)-NETs are the most common and NETs of the rectum represent 15, 2% of gastrointestinal malignancies....